Convalescent Plasma Collection and Treatment in Pediatrics and Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04376034|
Recruitment Status : Recruiting
First Posted : May 6, 2020
Last Update Posted : May 6, 2020
This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement. This study will include up to 240 participants potentially receiving convalescent plasma and up to 1000 potential donors.
There are 3 basic arms to the study: mild, moderate and severe/critical severity. All 3 severity groups are eligible for enrollment, but mild severity will not be given plasma unless there is progression. Moderate severity will given up to 1 unit of plasma and severe/critical severity up to 2 units. There is no placebo group, however given the excepted issues of shortages of plasma, intention to treat will be used for analysis.
|Condition or disease||Intervention/treatment||Phase|
|COVID19 Coronavirus Infection Coronavirus Virus Diseases RNA Virus Infections||Biological: Convalescent Plasma 1 Unit Biological: Convalescent Plasma 2 Units Other: Standard of Care||Phase 3|
Convalescent plasma (here on referred to as plasma) has been used in emergency life-threatening situations to treat infections for over 100 years. The plasma is donated by an individual that has recovered from the very same infection that another person is infected with. This plasma is enriched in the antibodies that recognize and helped the body's immune system fight off the infection. When transfused from donor to recipient those antibodies will aid the recipient in fighting off the infection. In recent history this has been used to fight Ebola. Recently, the Federal Food and Drug Agency (FDA) made possible expedited Investigational New Drug (IND) process for plasma use in the fight against COVID19 for emergency and lifesaving uses.
There are several other investigational drugs for treatment of COVID19 such as: Remdesivir, an antiviral. The off-label use of hydroxychloroquine, Lopinavir/ritonavir, or Tocilizumab have been authorized. Convalescent plasma mechanism of action helps to promote health by working with one's own immune system and will not interfere with the other proposed medications. It also will not weaken the immune system as the investigational and off label medications have the potential to do. Convalescent plasma is time honored and although investigational for each use against novel or rare infections, it is the basis for IgG infusions in the immunodeficient populations. Currently the use of IgG infusions such as Intravenous IgG (IVIG) is assumed to not have the right antibodies from donors in the general public. This is secondary to the novel nature of the COVID19 and the fact that the IVIG available today was collected 6 to 12 months ago from plasma donors; prior to the COVID19's outbreak discovery in China.
It is for that reason that IVIG is not recommended at this time and the FDA has made special fast-tracking announcements for plasma use for COVID19. Currently, plasma is the only treatment that has a previous history of success in these novel or rare viral outbreak situations. It has already been reported to have been associated with survival of 5 out of 5 participants in a pilot study in China
For the purpose of this study advanced respiratory support will include any measure of respiratory support above low flow nasal cannula oxygen (2 Liters/minute flow rate).
For the purpose of this study dyspnea will be defined as any shortness of breath that is not completely relieved with the use of low flow nasal canula oxygen set to 2 Liters/minute flow rate and/or requiring breathing treatments such as but not limited to: bronchodilators more than every 4 hours to relieve symptoms.
In the event that more than one recipient is identified and plasma is available in less than the total number of approved recipients, priority will be given to those approved by the FDA for the IND use of plasma for severe or critical condition. If there still exists a deficit of plasma, the priority will be given to those on advanced respiratory support with the most critical settings (if unclear then will be considered a tie); active pressor treatments; age <1 years of age with days of life, age adjusted for prematurity as a tie breaker; age >60 with years as a tie breaker; and lastly lottery pull with potential remaining recipients as the final tie breaker.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||240 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||Prospective intervention|
|Masking:||None (Open Label)|
|Official Title:||Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma|
|Actual Study Start Date :||April 16, 2020|
|Estimated Primary Completion Date :||March 30, 2021|
|Estimated Study Completion Date :||March 30, 2021|
Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.
Other: Standard of Care
Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
Active Comparator: Moderate Severity
Adult patients will be treated with 1 unit (200mL) of convalescent plasma
Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma.
Biological: Convalescent Plasma 1 Unit
Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.
Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma.
Active Comparator: Severe or Critical Severity
Adult patients will be treated with up to 2 units of convalescent plasma
Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma.
Biological: Convalescent Plasma 2 Units
Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.
Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.
Each pediatric recipient will receive 10mL/kg up to 2 units of plasma.
- Plasma Donor [ Time Frame: Measured in days for 365 days ]Time it takes to identify eligible donors whom are willing to donate
- Plasma Donor [ Time Frame: Measured in days for 365 days ]Time it takes the plasma collection center to contact willing donors whom are allowed to donate plasma
- Plasma Recipient [ Time Frame: Measured evey 24 hours up to 30 days ]Time from consent to infusion
- Plasma Recipient [ Time Frame: Measured in days with 30 day from discharge follow-up ]Survival
- Plasma Donor [ Time Frame: Measured every 24 hours up to 1 year ]Time until plasma is donated
- Plasma Recipient [ Time Frame: Day 1, 2, 3, 4, 7, and 30 day ]Incident of treatment-Emergent Adverse Events [Safety and Tolerability]
- Plasma Recipient [ Time Frame: Day 1, 2, 3, 4, 7, and 30 day ]Morbidity reduction
- Plasma Recipient [ Time Frame: Measured every 24 hours until patient discharged from hospital up to 1 year ]Reduced Length of Stay in hospital
- Plasma Recipient [ Time Frame: Measured every 24 hours until Off Advanced Respiratory Support up to 1 year ]Reduced Length of Stay on Advance Respiratory Support
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04376034
|Contact: Brian Peppers, DO, PhDfirstname.lastname@example.org|
|Contact: Lisa Giblin Sutton, PharmDemail@example.com|
|United States, West Virginia|
|Morgantown, West Virginia, United States, 26506|
|Principal Investigator:||Brian Peppers, DO, PhD||WVU Medicine Children's|